导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 42.23% | 18/350 |
| 近一周 | -1.97% | 186/358 |
| 近一月 | 5.19% | 16/358 |
| 近一季 | 20.10% | 29/358 |
| 近半年 | 11.31% | 133/354 |
| 近一年 | 34.21% | 28/345 |
| 近两年 | 40.57% | 89/310 |
| 近三年 | 21.00% | 159/242 |
| 成立以来 | -10.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
38.89% 8/360 |
-15.78% 351/366 |
- - |
- - |
| 2025 | -5.97% 324/358 |
-0.59% 192/340 |
-4.21% 321/348 |
4.15% 298/354 |
-5.18% 212/358 |
| 2024 | -0.74% 233/329 |
13.13% 17/280 |
-5.34% 233/310 |
-10.64% 303/318 |
3.72% 107/329 |
| 2023 | 3.73% 108/275 |
-6.64% 181/205 |
6.11% 93/230 |
15.73% 6/262 |
-9.52% 256/276 |
| 2022 | 56.58% 3/201 |
37.79% 2/153 |
-4.84% 72/164 |
11.07% 5/189 |
7.51% 120/202 |
| 2021 | 59.92% 6/150 |
38.98% 1/312 |
16.63% 20/328 |
0.85% 56/358 |
-2.17% 73/151 |
| 2020 | -30.31% 85/103 |
-57.28% 259/280 |
57.18% 2/295 |
-21.02% 292/299 |
31.41% 5/305 |
| 2019 | -9.57% 75/88 |
12.61% 79/258 |
-9.07% 252/268 |
-15.07% 244/253 |
4.00% 157/266 |
| 2018 | -23.84% 65/79 |
- - |
- - |
- - |
-37.42% 223/241 |
| 2017 | -15.41% 59/69 |
- - |
- - |
- - |
- - |
| 2016 | 44.24% 2/59 |
- - |
- - |
- - |
- - |
| 2015 | -34.78% 43/49 |
- - |
- - |
- - |
- - |
| 2014 | -32.23% 97/99 |
- - |
- - |
- - |
- - |
| 2013 | 18.39% 18/70 |
- - |
- - |
- - |
- - |
| 2012 | -3.27% 48/51 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2946 | 31.47% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3488 | 29.79% |
| 汇添富恒生生物科技ETF(QDII) | 1.1245 | 29.24% |
| 南方恒生生物科技ETF(QDII) | 1.1400 | 29.08% |
| 广发道琼斯石油指数美元现汇A | 0.4638 | 27.44% |
| 广发道琼斯石油指数美元现汇C | 0.4557 | 27.38% |
| 广发道琼斯石油指数(QDII-LOF)美元现汇E | 0.4568 | 27.33% |
| 南方恒生生物科技ETF发起联接(QDII)A | 1.2646 | 27.30% |
| 华夏恒生生物科技ETF发起式联接(QDII)C | 1.1472 | 27.25% |
| 汇添富恒生生物科技ETF发起式联接(QDII)C | 1.6358 | 27.22% |
| 华宝标普油气上游股票人民币A VS. 建信富时100指数(QDII)人民币A(539003) |